Timothy Patrick Coleman

US Patent:

6887464, May 3, 2005

Filed:

Feb 2, 2000

Appl. No.:

09/495947

Inventors:

Timothy P. Coleman - Rehoboth MA, US
Darrell L. Peterson - Chesterfield VA, US

Assignee:

BioCache Pharmaceuticals, Inc. - Richmond VA

International Classification:

A01N063/00
A61K048/00
A61K039/29
A61K039/30
A61K039/38
C12N007/01
C12N015/74

US Classification:

424 9321, 424 932, 4241841, 4241851, 4241891, 4352351, 4353201

Abstract:

The present invention provides particles for the presentation of haptens for the purpose of eliciting an immune response. The amino acid sequences of the monomers which make up the particles are derived from duck hepatitis B virus core protein. The particles may also deliver nucleic acids. The nucleic acids may be delivered for the purpose of enhancing an immune response, or for other purposes such as gene therapy.

US Patent:

20040219164, Nov 4, 2004

Filed:

Jun 1, 2004

Appl. No.:

10/857733

Inventors:

Timothy Coleman - Rehoboth MA, US
Darrell Peterson - Chesterfield VA, US

International Classification:

A61K039/29

US Classification:

424/189100, 514/044000

Abstract:

The present invention provides particles for the presentation of haptens for the purpose of eliciting an immune response. The amino acid sequences of the monomers which make up the particles are derived from duck hepatitis B virus core protein. The particles may also deliver nucleic acids. The nucleic acids may be delivered for the purpose of enhancing an immune response, or for other purposes such as gene therapy.

US Patent:

20120185409, Jul 19, 2012

Filed:

Nov 2, 2011

Appl. No.:

13/287758

Inventors:

Timothy P. Coleman - Wellesley MA, US
Jeffrey C. Heisler - Needham MA, US

International Classification:

G06Q 40/06

US Classification:

705 36 R

Abstract:

Systems and methods for securitizing the revenue stream of a product are disclosed. A system for securitizing the revenue stream of a product includes a primary market allowing a company to sell a percentage of the revenue of a product of the company to an investor, wherein the percentage of revenue stake in the product comprises issued shares; the bundling of the issued shares into various investment products; a secondary market providing liquidity for issued or bundled shares allowing the investor to trade these shares or bundles; retail market where these sales take place; wherein a transfer of the issued share from the company to the investor provides financial capital for the company without relinquishing an ownership stake in the company itself, and wherein when the product is sold, the investor is entitled to a percentage of revenues generated by sales of the product according to the issued shares.

US Patent:

20220218831, Jul 14, 2022

Filed:

Apr 30, 2020

Appl. No.:

17/607586

Inventors:

- Wellesley MA, US
Timothy Patrick COLEMAN - Wellesley MA, US

International Classification:

A61K 47/54
A61P 35/00

Abstract:

Provided herein are compounds, which act as protein degradation inducing moieties for aurora kinase (AURK). The present application also relates to methods for the targeted degradation of AURK through the use of the compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to AURK which can be utilized in the treatment of disorders modulated by AURK.

US Patent:

20160166507, Jun 16, 2016

Filed:

Jul 25, 2014

Appl. No.:

14/907422

Inventors:

- Worcester MA, US
Timothy P. COLEMAN - Wellesley MA, US

Assignee:

NEMUCORE MEDICAL INNOVATIONS, INC. - Worcester MA

International Classification:

A61K 9/107
A61K 47/48
A61K 49/10
A61K 49/18
A61K 31/282
A61K 31/606

Abstract:

Provided are nanoemulsion formulations useful for the delivery of hydrophobic platinum chemotherapeutic drugs to cancer patients, as well as methods of their preparation and use.

US Patent:

20140105829, Apr 17, 2014

Filed:

Oct 15, 2013

Appl. No.:

14/053754

Inventors:

- Worcester MA, US
Timothy P. Coleman - Wellesley MA, US

Assignee:

Nemucore Medical Innovations, Inc. - Worcester MA

International Classification:

A61K 9/107
A61K 49/18
A61K 31/337

US Classification:

424 9364, 514449, 4241741, 424 93, 435375

Abstract:

A novel nanoemulsion formulation useful for the delivery of docetaxel chemotherapeutic agents is provided, as well as methods of their preparation and use in cancer patients and for cancer imaging.